TESARO (TSRO) : Traders are bullish on TESARO (TSRO) as it has outperformed the S&P 500 by a wide margin of 8.32% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 3.15%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 3.2% in the last 1 week, and is up 9.44% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 4.43% and the 50-Day Moving Average is 33.88%. TESARO (NASDAQ:TSRO): stock turned positive on Friday. Though the stock opened at $94, the bulls momentum made the stock top out at $96.76 level for the day. The stock recorded a low of $92.725 and closed the trading day at $96.36, in the green by 3.17%. The total traded volume for the day was 1,551,832. The stock had closed at $93.4 in the previous days trading.
The company Insiders own 40.5% of TESARO shares according to the proxy statements. Institutional Investors own 91.56% of TESARO shares. During last six month period, the net percent change held by insiders has seen a change of 8.02%. Also, RBC Capital initiates coverage on TESARO (NASDAQ:TSRO). The shares have now been rated Outperform by the stock experts at the ratings house. The rating by the firm was issued on August 12, 2016.
TESARO, Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates, rolapitant, niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib, formerly known as MK-4827, is an orally active and potent poly (ADP-ribose) polymerase, and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio, Inc., for the discovery and development of antibodies for several specified immuno-oncology targets.